Frontier IP Group Plc (FIPP.L) Announced that its portfolio company Exscientia (Exscientia), a world leader in artificial intelligence (AI) drug discovery, has entered into a drug-discovery partnership with GT Apeiron Therapeutics (GT Apeiron). GT Apeiron is a Shanghai-headquartered biotechnology drug-discovery platform launched with $27 million backing from GT Healthcare Capital Partners (GT Healthcare), a life sciences-focused private equity partnership. GT Healthcare is also an investor in Exscientia. As part of the agreement, Exscientia is entitled to become a shareholder in GT Apeiron as well as receiving milestones and royalties based on the clinical and commercial success of each programme
Login or register to post comments